Endoscopic ultrasound-guided radiofrequency ablation in a pancreatic neuroendocrine tumor: expanding access to minimally invasive therapies

Authors

DOI:

https://doi.org/10.22516/25007440.1494

Keywords:

Endoscopic ultrasonography, neuroendocrine tumor, radiofrequency ablation

Abstract

Introduction: Pancreatic neuroendocrine tumors (pNETs) are uncommon neoplasms that originate in pancreatic islet cells and account for 1%-2% of all pancreatic tumors.

Case presentation: We present the case of a 47-year-old man with multiple pathological conditions and previous abdominal surgical interventions who sought medical care because of persistent elevation of liver enzymes. Magnetic resonance cholangiography showed an 18 mm solid lesion in the pancreatic body. Endoscopic ultrasonography (EUS) identified a well-defined, hypoechoic, hypervascular nodule. Fine-needle biopsy (FNB) confirmed a well-differentiated grade 1 pNET (Ki-67 1%). PET-CT with 68Ga-DOTA showed focal uptake consistent with a pNET. After a multidisciplinary discussion, the team chose EUS-guided radiofrequency ablation (EUS-RFA) because of the high surgical risk associated with the patient’s comorbidities and previous abdominal surgeries. Under general anesthesia, the team applied 30 W in continuous mode through a 19 G radiofrequency needle until achieving complete ablation.

Results: No immediate complications occurred. Computed tomography one week later confirmed complete tumor ablation without residual enhancement.

Conclusions: This case is consistent with international reports showing high efficacy and a low complication rate with EUS-RFA. However, the technique is not free of risks (pancreatitis, bleeding, perforation), which were not observed in this patient. As one of the first experiences in Latin America and, to the best of current knowledge, in Colombia, this case highlights that EUS-RFA is a promising minimally invasive alternative for selected pNETs. Regional cohorts are required to characterize risks and population-specific features, and comparative evaluations against active surveillance and surgery are justified.

Downloads

Download data is not yet available.

Author Biographies

Renzo Pinto Carta, Fundación Santa Fe de Bogotá

Institutional Gastroenterologist, Fundación Santa Fe. Bogotá, Colombia.

Camilo Humberto Soler Becerra, Fundación Santa Fe de Bogotá

Radiologist, Abdominal Imaging Fellow, Fundación Santa Fe. Bogotá, Colombia.

Maria Alejandra Gomez Gutierrez, Fundación Santa Fe de Bogotá

Physician, Research Assistant, Fundación Santa Fe. Bogotá, Colombia.

Laura Olarte Bermudez, Fundación Santa Fe de Bogotá

General Practitioner, Rural Research Assistant, Fundación Santa Fe. Bogotá, Colombia.

Fernando Sierra Arango, Fundación Santa Fe de Bogotá

Physician, MSc, Director of the Subdirectorate of Clinical Studies, Head of the Department of Gastroenterology, Fundación Santa Fe. Bogotá, Colombia.

References

Ohmoto A, Rokutan H, Yachida S. Pancreatic neuroendocrine neoplasms: Basic biology, current treatment strategies and prospects for the future. Int J Mol Sci 2017;18(1):143. https://doi.org/10.3390/ijms18010143

Kos-Kudła B, Castaño JP, Denecke T, Grande E, Kjaer A, Koumarianou A, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35(12):e14242. https://doi.org/10.1111/jne.13343

Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500-16. https://doi.org/10.1148/rg.352140164

Barthet M, Giovannini M, Gasmi M, Lesavre N, Boustière C, Napoleon B, et al. Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms. Endosc Int Open. 2021;9(8):E1178-E1185. https://doi.org/10.1055/a-1479-2199

Napoléon B, Lisotti A, Caillol F, Gasmi M, Ah-Soune P, Belle A, et al. Risk factors for EUS-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study). Gastrointest Endosc. 2023;98(3):392-399.e1. https://doi.org/10.1016/j.gie.2023.04.003

Coluccio C, Cappetta S, Romagnoli G, Di Giorgio V, Giuffrida P, Fabbri S, et al. Endoscopic-Ultrasound-Guided Radiofrequency Ablation for Pancreatic Tumors. J Clin Med. 2025;14(2):495. https://doi.org/10.3390/jcm14020495

Khoury T, Sbeit W, Napoléon B. Endoscopic ultrasound guided radiofrequency ablation for pancreatic tumors: A critical review focusing on safety, efficacy and controversies. World J Gastroenterol. 2023;29(1):157-170. https://doi.org/10.3748/wjg.v29.i1.157

Figure 1. Axial (A) and sagittal (B) computed tomography (CT) images of the abdomen and pelvis obtained before ablation. Image courtesy of the authors.

Published

2026-09-11

How to Cite

Pinto Carta, R., Soler Becerra, C. H., Gomez Gutierrez, M. A., Olarte Bermudez, L., & Sierra Arango, F. (2026). Endoscopic ultrasound-guided radiofrequency ablation in a pancreatic neuroendocrine tumor: expanding access to minimally invasive therapies. Revista Colombiana De Gastroenterología, 41(3), 363–367. https://doi.org/10.22516/25007440.1494

Altmetric

Escanea para compartir
QR Code
Crossref Cited-by logo
Article metrics
Abstract views12
Galley views6
PDF Views6
HTML views0
Other views0

Some similar items: